Information Provided By:
Fly News Breaks for January 16, 2020
BTAI
Jan 16, 2020 | 07:51 EDT
BMO Capital analyst Do Kim raised his price target on BioXcel Therapeutics to $26 and kept his Outperform rating after his meeting with its management. The analyst notes that the presentation highlighted the company's plans to expand its BXCL501 program across the agitation disorder spectrum, which includes the pre- to chronic agitation and severe, aggressive agitation. Kim believes that the BXCL501 opportunity is underappreciated and the positive trial data is de-risking BioXcel's ongoing development of expansion programs.